Attune Pharmaceuticals

Attune Pharmaceuticals, founded in 2015 and headquartered in New York, USA, is a privately-held clinical-stage biotechnology R&D company dedicated to exploring and developing novel oral small-molecule drugs for the treatment of rare diseases. Attune is currently advancing two programs: one for Hereditary Angioedema (HAE) and the other for complement-mediated diseases.